Topic:

Emerging Markets

Latest Headlines

Latest Headlines

Parexel eyes the Middle East with its latest CRO buyout

Parexel International is looking to broaden its presence in the Middle East and North Africa, snapping up Turkish CRO Atlas Medical Services.

Intuitive Surgical kicks off da Vinci sales in Japan

Intuitive Surgical is kicking off direct sales of its da Vinci Surgical Systems in Japan, continuing its push in emerging markets and hoping to generate positive numbers after a year of sluggish sales.

Cipla buys capacity in Yemen with deal to control company there

India-based Cipla has been expanding its manufacturing footprint outside of its base in India and has now made the jump across the Arabian Sea to Yemen.

Korean pharma booster recruits Novotech to boost local R&D

Novotech, which bills itself as Australia's largest CRO, has signed a deal with a South Korean outfit to help bolster the country's status among global drug development locales.

Inspired by a plunger, new device cuts wound-healing costs

A team from the Massachusetts Institute of Technology is a finalist for the 2014 Hult Prize after developing a simple wound-therapy device to improve the lives of those lacking access to adequate medical care.

Roche and Cipla are ordered to mediate in a new twist on Indian IP fights

Roche and Cipla are writing a new chapter in the bitter battles that have been fought by Western drugmakers over their patents in India. They are in mediation over the patent for Roche's blockbuster cancer fighter Tarceva, in what may be the first case to take this route.

What's the cure for China's corruption crackdown? Hire more locals

Big Pharma's reputation in China has taken a bruising in the last year after an investigation into GlaxoSmithKline's use of bribery to power sales there spilled over to questions into Roche, Novo Nordisk and others. So what's the industry to do to burnish its image and smooth over the situation with authorities? Hire Chinese nationals who can figure out the puzzle box that is Chinese healthcare.

Dr. Reddy's avoids pitfalls of Ranbaxy, Wockhardt by cutting workers out of production

To avoid the fate of some of its competitors that have run afoul of the FDA over loose manufacturing standards, Dr. Reddy's and some other Indian drugmakers have decided it is worth investing hundreds of millions of dollars for new plants and equipment in a country that has traditionally relied on cheap human labor.

Celerion moves into Singapore amid Asian expansion

Lincoln, NE, CRO Celerion has opened up shop in Singapore, following through on its efforts to tap the fast-growing Asian market for clinical research.

Turkey's drugmakers expand manufacturing as market booms

Turkey is a fast-growing market expected to be worth about $22.8 billion by the end of 2015. Domestic drugmakers, along with Big Pharma, are expanding manufacturing there to keep up with demand.